Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells

Abstract

Survivin is a new member of the inhibitor of apoptosis protein (IAP) family that is implicated in the control of cell proliferation and the regulation of cell life span. This protein is selectively expressed in most human carcinomas but not in normal adult tissues. To down-regulate a human survivin expression as a strategy for cancer gene therapy, we designed two hammerhead ribozymes (RZ-1, RZ-2) targeting human survivin mRNA. RZ-1 and RZ-2 efficiently cleaved the human survivin mRNA at nucleotide positions +279 and +289, which was identified by in vitro cleavage assay using in vitro transcribed ribozymes and truncated survivin mRNA substrate. To investigate the function of the ribozymes in cells, the sequences of the ribozymes were cloned into replication-deficient adenoviral vector and transferred to breast cancer cell, MCF-7. The infection with adenovirus encoding the ribozymes resulted in a significant reduction of survivin mRNA (74% and 73%, respectively) and protein. As revealed by nuclear condensation/ fragmentation and flow cytometry analysis, inhibition of survivin gene by ribozymes increased apoptosis and sensitivity induced by etoposide or serum starvation. Our results suggest that the designed hammerhead ribozymes against survivin mRNA are good candidates for feasible gene therapy in the treatment of cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Nagata S . Apoptosis by death factor. Cell. 1997;88:355–365.

    Article  CAS  Google Scholar 

  2. Vaux DL, Haecker G, Strasser A . An evolutionary perspective on apoptosis. Cell. 1994;76:777–779.

    Article  CAS  Google Scholar 

  3. Thompson CB . Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462.

    Article  CAS  Google Scholar 

  4. Adams JM, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326.

    Article  CAS  Google Scholar 

  5. Deveraux QL, Reed JC . IAP family proteins — suppressors of apoptosis. Genes Dev. 1999;13:239–252.

    Article  CAS  Google Scholar 

  6. Lacasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–3259.

    Article  Google Scholar 

  7. Birnbaum MJ, Clem RJ, Miller LK . An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol. 1994;68:2521–2528.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Crook NE, Clem RJ, Miller LK . An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993;67:2168–2174.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Ambrosini G, Adida C, Altieri DC . A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921.

    Article  CAS  Google Scholar 

  10. Chiodino C, Cesinaro AM, Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol. 1999;113:415–418.

    Article  CAS  Google Scholar 

  11. Konno R, Yamakawa H, Utsunomiya H, et al. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod. 2000;6:529–534.

    Article  CAS  Google Scholar 

  12. Jiang X, Wilford C, Duensing S, et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem. 2001;83:342–354.

    Article  CAS  Google Scholar 

  13. Monzo M, Rosell R, Felip E, et al. Novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1997;17:2100–2104.

    Article  Google Scholar 

  14. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–134.

    CAS  PubMed  Google Scholar 

  15. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin shorter survival rates in colorectal cancers. Cancer Res. 1998;58:5071–5074.

    CAS  PubMed  Google Scholar 

  16. Lu CD, Altieri DC, Tanigawa N . Expression of novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808–1812.

    CAS  PubMed  Google Scholar 

  17. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–95.

    Article  CAS  Google Scholar 

  18. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271–278.

    Article  CAS  Google Scholar 

  19. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the anti-apoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452–453.

    Article  CAS  Google Scholar 

  20. Saitoh Y, Yaginuma Y, Ishikawa M . Analysis of Bcl-2, Bax and survivin genes in uterine cancer. Int J Oncol. 1999;15:137–141.

    CAS  PubMed  Google Scholar 

  21. Yoshida H, Ishiko O, Sumi T, et al. Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol. 2001;19:537–542.

    CAS  PubMed  Google Scholar 

  22. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925.

    CAS  PubMed  Google Scholar 

  23. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukemia. Br J Haematol. 2000;111:196–203.

    Article  CAS  Google Scholar 

  24. Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukemia: survivin is important determinant for prognosis. Br J Haematol. 2001;114:63–69.

    Article  CAS  Google Scholar 

  25. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–883.

    Article  CAS  Google Scholar 

  26. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–623.

    Article  CAS  Google Scholar 

  27. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–1081.

    Article  CAS  Google Scholar 

  28. Grossman D, McNiff JM, Li F, et al. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79:1121–1126.

    CAS  PubMed  Google Scholar 

  29. Sullivan S . Development of ribozymes for gene therapy. J Invest Dermatol. 1994;103:85S–95S.

    Article  CAS  Google Scholar 

  30. Haseloff J, Gerlach WL . Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988;334:585–591.

    Article  CAS  Google Scholar 

  31. Stein CA . Does antisense exists? Nat Med. 1995;1:1119–1121.

    Article  CAS  Google Scholar 

  32. Wagner RW . Toward a broad-based antisense technology. Antisense Res Dev. 1995;5:113–114.

    Article  CAS  Google Scholar 

  33. Yokoyama Y, Morishita S, Takahashi Y, et al. Modulation of c-fos proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme. Br J Cancer. 1997;76:977–982.

    Article  CAS  Google Scholar 

  34. Kashani-Sabet M, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev. 1992;2:3–15.

    Article  CAS  Google Scholar 

  35. Lavrovsky Y, Tyagi RK, Chen S, et al. Ribozyme-mediated cleavage of the estrogen receptor messenger RNA and inhibition of receptor function in target cells. Mol Endocrinol. 1999;13:925–934.

    Article  CAS  Google Scholar 

  36. Chen S, Song CS, Lavrovsky Y, et al. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol. 1998;12:1558–1566.

    Article  CAS  Google Scholar 

  37. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1999;1:461–466.

    Article  CAS  Google Scholar 

  38. Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia. 2000;2:235–241.

    Article  CAS  Google Scholar 

  39. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805–2809.

    CAS  PubMed  Google Scholar 

  40. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182.

    Article  CAS  Google Scholar 

  41. Kanwar JR, Shen WP, Kanwar RK, et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001;93:1541–1552.

    Article  CAS  Google Scholar 

  42. Kallio MJ, Nieminen M, Eriksson JE . Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J. 2001;15:2721–2723.

    Article  CAS  Google Scholar 

  43. Shankar SL, Mani S, O'Guin KN, et al. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem. 2001;79:426–436.

    Article  CAS  Google Scholar 

  44. Grossman D, Kim PJ, Schechner JS, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci. 2001;98:635–640.

    Article  CAS  Google Scholar 

  45. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981–990.

    Article  CAS  Google Scholar 

  46. Guo S, Kemphues KJ . par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 1995;81:611–620.

    Article  CAS  Google Scholar 

  47. Hendrix C, Anne J, Joris B, et al. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem J. 1996;314:655–661.

    Article  CAS  Google Scholar 

  48. Fedor MJ, Uhlenbeck OC . Substrate sequence effects on “hammerhead” RNA catalytic efficiency. Proc Natl Acad Sci. 1990;87:1668–1672.

    Article  CAS  Google Scholar 

  49. Herschlag D, Cech TR . Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme: 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry. 1990;29:10172–10180.

    Article  CAS  Google Scholar 

  50. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–6102.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Myeong Ho Jung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, K., Lee, T. & Jung, M. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 10, 87–95 (2003). https://doi.org/10.1038/sj.cgt.7700531

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700531

Keywords

This article is cited by

Search

Quick links